1Yancovitz M, Yoon J, Mikhail M, et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn, 2007,9:178-183.
2Levenson VV. Biomarkers for early detection of breast cancer: what, when and where? Biochim Biophys Acta, 2007,1770:847- 856.
3Schmidt K, Diehl F. A blood-based DNA test for colorectal cancer screening. Discov Med, 2007,7:7 -12.
4Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res, 1977, 37:646-650.
5Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis cell promoter methylation analysis in tumor tissues, serum and plasma DNA of patients with lung cancer. Cancer Res, 2002,2:371-375.
6Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science, 1996,274: 2057-2059.
7Deng G, Chen A, Hong J, et al. Methylation of CpG in a small region of the hMLH1 promoter Invariably correlates with the absence of gene expression. Cancer Res, 1999,59:2029-2033.
8Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible association with male sex and KRAS mutations. J Mol Diagn, 2006,8:582-588.
9Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucl Acids Res, 2000,28 :e32.
10Widschwandter M, Siegmund KD, Muller HM, et al. Association of breast cancer methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res,2004 ,64 :3807-3813.
